Literature DB >> 29105964

Simultaneous transcatheter transfemoral aortic and transeptal mitral valve replacement using Edward SAPIEN S3.

Zaher Fanari1,2, Hadi Mahmaljy3, Shalish Nandish1, Nilesh J Goswami1.   

Abstract

Patients with concomitant severe aortic stenosis (AS) and severe mitral stenosis (MS) with mitral annular calcification (MAC) constitute an elderly high-risk population with multiple baseline comorbidities that coexist even before they develop severe valvular dysfunction. Transcatheter mitral valve replacements (TMVR) offer an alternative option for high-risk patient with severe MS with MAC. A simultaneous transfemoral Transcatheter aortic valve replacement (TAVR) and transseptal TMVR is feasible and offers the least invasive approach of management. We are reporting a case of an 83-year-old man with very symptomatic severe AS and severe native MS with associated severe MAC and moderate mitral regurgitation with high STS score who underwent a simultaneous transfemoral TAVR and transseptal TMVR with good results and great improvement in symptoms that was maintained on 10 months follow-up.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  transcatheter aortic valve replacement; transcatheter mitral valve replacement; transeptal access; transfemoral access

Mesh:

Year:  2017        PMID: 29105964     DOI: 10.1002/ccd.27410

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  Simultaneous transcatheter valve-in-valve replacement of severely degenerated bioprosthetic aortic and mitral prostheses.

Authors:  Hendrik Wienemann; Victor Mauri; Elmar Kuhn; Stephan Baldus; Matti Adam
Journal:  Clin Res Cardiol       Date:  2022-08-04       Impact factor: 6.138

2.  Simultaneous Transcatheter Double Valve Treatment of Mediastinal Radiation-Induced Severe Calcific Aortic and Mitral Stenosis.

Authors:  Christopher J Allen; Tiffany Patterson; Bernard Prendergast; Ross L Roberts-Thompson; Ronak Rajani; Simon R Redwood
Journal:  JACC Case Rep       Date:  2020-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.